Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2OCZ8)

• Drug Name: doxorubicin-peptide-PEG conjugate Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID: TTD Drug ID: DM2OCZ8

Molecule-Related Drug Atlas

Drug(s) Targeting Human Deoxyribonucleic acid (hDNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[2]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[3]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[4]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[5]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[6]
Carboplatin	DMG281S	Adenocarcinoma	2D40	Approved	[7]
Busulfan	DMXYJ9C	Chronic myelogenous leukaemia	2A20.0	Approved	[8]
Procarbazine	DMIK367	Hodgkin lymphoma	2B30	Approved	[9]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[10]
Dacarbazine	DMNPZL4	Adenocarcinoma	2D40	Approved	[11]

Drug(s) Targeting DNA topoisomerase II (TOP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[12]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[13]
Teniposide	DMLW57T	Acute lymphoblastic leukaemia	2A85	Approved	[12]
Mitoxantrone	DMM39BF	Acute myelogenous leukaemia	2A41	Approved	[14]
Idarubicin	DMM0XGL	Acute myelogenous leukaemia	2A41	Approved	[12]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[12]
Lomefloxacin	DMVRH9C	Bacterial infection	1A00-1C4Z	Approved	[15]
Dexrazoxane	DMD7X1O	Breast cancer	2C60-2C65	Approved	[12]
Podofilox	DMT2EJP	Condyloma	1A95	Approved	[16]
Enoxacin	DMYTE6L	Acute gonococcal cervicitis		Approved	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN; TOP2B_HUMAN	Modulator	[1]
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Modulator	[1]

References

• [1] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [2] Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
• [3] Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
• [4] 31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
• [5] Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
• [6] O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
• [7] Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
• [8] DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.
• [9] Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
• [10] Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
• [11] Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [13] Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
• [14] Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
• [15] Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
• [16] Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
• [17] Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.